News ID: 133689
Published: 0307 GMT December 26, 2015

Targeting fat-tissue hormone may treat type 2 diabetes

Targeting fat-tissue hormone may treat type 2 diabetes

A new study by researchers from Harvard University describes the preclinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

The researchers developed an antibody that improves glucose regulation and reduces fatty liver in obese mice by targeting a hormone in adipose (fat) tissue called ‘aP2’ (also known as ‘FABP4’), Medical Xpress wrote.

"The importance of the study is two-fold: First, demonstrating the importance of aP2 as a critical hormone in abnormal glucose metabolism, and secondly, showing that aP2 can be effectively targeted to treat diabetes and potentially other immunometabolic diseases," said Gökhan S. Hotamisligil, J.S. Simmons, professor of Genetics and Metabolism and chair of the Department of Genetics and Complex Diseases and the Sabri Ülker Center at Harvard Chan School.

The increase in adipose tissue characteristic of obesity has long been linked to increased risk for metabolic diseases such as type 2 diabetes and cardiovascular disease. Recently, it has become clear that the tissue itself plays an active role in metabolic disease, in part by releasing hormones which act in distant sites such as the liver, muscle, and brain that affect systemic metabolism.

Work from the Hotamisligil lab previously identified the protein aP2 as a critical hormone mediating communication between adipose tissue and liver. Since aP2 levels significantly increase in humans with obesity, diabetes, and atherosclerosis, and mutations that reduce aP2 result in significantly reduced risk of diabetes, dyslipidemia, and heart disease, strategies to modify aP2 function carry promise as new lines of therapeutic entities against these common and debilitating chronic diseases.

In the new study, researchers describe the development and evaluation of novel monoclonal antibodies targeting aP2. The team found that one of these antibodies effectively improved glucose regulation in two independent models of obesity. Additionally, beneficial reductions in liver fat were observed.

These monoclonal antibodies have the potential to be transformative first-in-class therapeutics to fight obesity-related metabolic and immunometabolic disease, said the authors. This work is still at the preclinical stage and will require extensive evaluation for safety and effectiveness before being considered for use in humans.

 

   
KeyWords
 
Comments
Comment
Name:
Email:
Comment:
Security Key:
Captcha refresh
Page Generated in 0/2477 sec